Annefleur D. O. Hensen

Annefleur D. O. Hensen

Auto-generated profile, based on publicly available information

Annefleur D. O. Hensen

Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2025 in Nature Medicine
Verified
Journal Article
Open access
PDF file
GRGeert Roozen
Geert Roozen
RSRoos van Schuijlenburg
Roos van Schuijlenburg
AHAnnefleur D. O. Hensen
Annefleur D. O. Hensen
JKJan Pieter R. Koopman
Jan Pieter R. Koopman
OLOlivia A. C. Lamers
Olivia A. C. Lamers
MRMeta Roestenberg
Meta Roestenberg
Malaria vaccines consisting of metabolically active Plasmodium falciparum (Pf) sporozoites can offer improved protection compared with currently deployed subunit vaccines. In a previous study, we demonstrated the superior protective efficacy of a three-dose regimen of late-arresting genetically attenuated parasites administered by mosquito bite (GA2-MB) compared with early-arresting counterparts (GA1-MB) against a homologous controlled human malaria infection. Encouraged by these results, we explored the potency of a single GA2-MB immunization in a placebo-controlled randomized trial. Primary outcomes were safety and tolerability, time-to-parasitemia and protective efficacy. Humoral and cellular immunological results were considered secondary outcomes. Here we report the safe administration of GA2-MB with no breakthrough malaria and sterile protection in nine of ten participants at 6 weeks after a single immunization with 50 GA2-infected mosquitoes, compared with none of five mock-immunized participants, against a homologous controlled human malaria infection. Immunization increased circulating Pf-specific polyfunctional effector memory CD4+ T cells coexpressing tumor necrosis factor and interleukin-2. This unprecedented 90% protective efficacy after a single low-dose immunization holds great promise for the potency of GA2 immunization. Future studies should demonstrate whether GA2 is similarly efficacious in pre-exposed populations and whether the favorable safety profile reported here holds up in larger groups. ClinicalTrials.gov registration: NCT05468606.

12 June 2026 in Nature Communications
Verified
Journal Article
Open access
AHA. D. O. Hensen
A. D. O. Hensen
CHC. Harmanus
C. Harmanus
PVP. H. Verbeek-Menken
P. H. Verbeek-Menken
JKJ. P. R. Koopman
J. P. R. Koopman
OLO. A. C. Lamers
O. A. C. Lamers
MRMeta Roestenberg
Meta Roestenberg
Clostridioides difficile infections remain a major global healthcare burden, underscoring the need for novel therapies. Human colonisation models provide mechanistic insight into C. difficile colonisation and facilitate identification of novel intervention targets. We conducted a placebo-controlled, randomised clinical trial (NCT05693077) administering non-toxigenic C. difficile (NTCD) capsules to healthy participants to assess safety and colonisation as primary endpoints, and microbiota susceptibility as a secondary endpoint. A total of 69 healthy participants (18-45 years), not previously colonised with C. difficile and without recent antibiotic use, were enrolled following a health assessment. NTCD capsules administered for five consecutive days at low or high dose, was safe with no dose-response relationship in colonisation outcomes. Vancomycin pretreatment induced colonisation success: with 5% colonisation without, 32% after one day, and 84% after five days vancomycin pretreatment. Some participants that cleared vancomycin rapidly acquired non-challenge C. difficile strains prior to NTCD challenge. Microbiota profiling (using shotgun metagenomics) revealed reduced α-diversity and pronounced community restructuring. These findings highlight the impact of antibiotic-mediated microbiota disruption, the widespread environmental presence of C. difficile, and the feasibility of meaningful microbiota assessment in small-scale intervention trials, thereby providing a robust tool to investigate this globally impactful infection.

9 December 2025 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
AHAnnefleur D O Hensen
Annefleur D O Hensen
CHCéline Harmanus
Céline Harmanus
CVChristine Voorvelt
Christine Voorvelt
AGAnoecim R Geelen
Anoecim R Geelen
MHMaryam El Hamdioui
Maryam El Hamdioui
WSWiep Klaas Smits
Wiep Klaas Smits
Background: Infections with Clostridioides difficile remain a significant global healthcare problem for which novel (preventive) treatment strategies are urgently needed. Controlled human infection models (CHIMs) can contribute to a better understanding of the disease and accelerate (novel) medicinal product development. Methods: A robust production process for C difficile spores for experimental human administration was implemented. Direct-release capsules containing viable C difficile spores were formulated. The manufacturing process aligns with Good Manufacturing Practice (GMP) guidelines, including quality controls and release by a Qualified Person (QP). Results: Selected nontoxigenic and toxigenic C difficile strains were used to create a master cell bank and working cell bank from which multiple batches of purified active substance were produced. Substance was then used to manufacture the final active product. The active product and its intermediate products passed all quality controls for identity, potency, purity and safety, and were individually released by the QP. Stability of active substance and product is confirmed up to 12 months. Conclusions: Although there are no clear standardized international guidelines for challenge material production, we demonstrate that it is feasible to produce C difficile human challenge material for small-scale application in CHIM trials. This application of GMP principles to an unconventional production process of a bacterial spore-forming anaerobic challenge agent is an example for the production of challenge material as described in the auxiliary medicinal product guidelines of the European Medicines Agency and the US Food and Drug Administration.

16 September 2025 in bioRxiv
Verified
Preprint
Open access
AHAnnefleur D.O. Hensen
Annefleur D.O. Hensen
CHCéline Harmanus
Céline Harmanus
CVChristine Voorvelt
Christine Voorvelt
AGAnoecim R. Geelen
Anoecim R. Geelen
MHMaryam El Hamdioui
Maryam El Hamdioui
WSWiep Klaas Smits
Wiep Klaas Smits
Background: Infections with C. difficile remain a significant global healthcare problem for which novel (preventive) treatment strategies are urgently needed. Controlled human infection models (CHIMs) can contribute to a better understanding of the disease and accelerate (novel) medicinal product development. Methods: A robust production process for C. difficile spores for experimental human administration, was implemented. Direct-release capsules containing viable C. difficile spores were formulated. The manufacturing process aligns with good manufacturing practices (GMP) guidelines, including quality controls and release by a qualified person (QP). Results: Selected non-toxigenic and toxigenic C. difficile strains were used to create a master cell bank and working cell bank from which multiple batches of purified active substance were produced. Substance was then used to manufacture the final active product. The active product and its intermediate products passed all quality controls for identity, potency, purity and safety, and were individually released by the QP. Stability of active substance and product is confirmed up to 12 months. Conclusion: Although there are no clear standardized international guidelines for challenge material production, we demonstrate that it is feasible to produce C. difficile human challenge material for small scale application in CHIM trials. This application of GMP principles to an unconventional production process of a bacterial spore-forming anaerobic challenge agent is an example for the production of challenge material as described in the auxiliary medicinal product guidelines of EMA and FDA.

22 June 2026 in Biologicals
Verified
Journal Article
Closed access
VCVictor Cnossen
Victor Cnossen
AHAnnefleur Hensen
Annefleur Hensen
LPLaura Pattacini
Laura Pattacini
PAPepijn Al
Pepijn Al
ADAnna Durbin
Anna Durbin
MHMarie-Astrid Hoogerwerf
Marie-Astrid Hoogerwerf